

Lucia Altucci

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5895075/lucia-altucci-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

271
papers

15,064
citations

57
h-index

115
g-index

297
ext. papers

17,787
ext. citations

7.1
avg, IF

6.3
L-index

#	Paper	IF	Citations
271	HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation.. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022 , 41, 83	12.8	1
270	Heterocycle-containing tranylcypromine derivatives endowed with high anti-LSD1 activity.. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2022 , 37, 973-985	5.6	0
269	Single-Cell Photothermal Analysis Induced by MoS Nanoparticles by Raman Spectroscopy.. <i>Frontiers in Bioengineering and Biotechnology</i> , 2022 , 10, 844011	5.8	
268	Design and synthesis of multifunctional microtubule targeting agents endowed with dual pro-apoptotic and anti-autophagic efficacy.. <i>European Journal of Medicinal Chemistry</i> , 2022 , 235, 114274	6.8	0
267	Azetidin-2-one-based small molecules as dual hHDAC6/HDAC8 inhibitors: Investigation of their mechanism of action and impact of dual inhibition profile on cell viability.. <i>European Journal of Medicinal Chemistry</i> , 2022 , 238, 114409	6.8	0
266	HIF3A Inhibition Triggers Browning of White Adipocytes Metabolic Rewiring.. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 740203	5.7	
265	Effects of novel SGLT2 inhibitors on cancer incidence in hyperglycemic patients: a meta-analysis of randomized clinical trials.. <i>Pharmacological Research</i> , 2021 , 175, 106039	10.2	3
264	(INVITED)Quantitative detection of SARS-CoV-2 virions in aqueous mediums by IoT optical fiber sensors. <i>Results in Optics</i> , 2021 , 5, 100177	1	2
263	DNA Mutations via Chern-Simons Currents. <i>European Physical Journal Plus</i> , 2021 , 136, 1080	3.1	1
262	KDM4 Involvement in Breast Cancer and Possible Therapeutic Approaches. <i>Frontiers in Oncology</i> , 2021 , 11, 750315	5.3	2
261	Recent insights into : biological function and involvement in pathogenesis. <i>Epigenetics</i> , 2021 , 16, 838-850	5.7	6
260	The Two-Faced Role of SIRT6 in Cancer. <i>Cancers</i> , 2021 , 13,	6.6	8
259	Gene Transactivation and Transrepression in MYC-Driven Cancers. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	8
258	Clinical epigenetics settings for cancer and cardiovascular diseases: real-life applications of network medicine at the bedside. <i>Clinical Epigenetics</i> , 2021 , 13, 66	7.7	9
257	Discovery of novel tetrahydrobenzo[b]thiophene-3-carbonitriles as histone deacetylase inhibitors. <i>Bioorganic Chemistry</i> , 2021 , 110, 104801	5.1	0
256	Toward a Personalized Therapy in Soft-Tissue Sarcomas: State of the Art and Future Directions. <i>Cancers</i> , 2021 , 13,	6.6	1
255	Antiviral Activity of Leaf Extract against SARS-CoV-2 and HSV-1. <i>Viruses</i> , 2021 , 13,	6.2	19

254	Epigenetic mechanisms underlying prostate cancer radioresistance. <i>Clinical Epigenetics</i> , 2021 , 13, 125	7.7	7
253	Harnessing the Role of HDAC6 in Idiopathic Pulmonary Fibrosis: Design, Synthesis, Structural Analysis, and Biological Evaluation of Potent Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2021 , 64, 9960-9988	8.3	5
252	Different Approaches to Unveil Biomolecule Configurations and Their Mutual Interactions. <i>Analytical Letters</i> , 2021 , 54, 40-56	2.2	0
251	Novel quinolone-based potent and selective HDAC6 inhibitors: Synthesis, molecular modeling studies and biological investigation. <i>European Journal of Medicinal Chemistry</i> , 2021 , 212, 112998	6.8	7
250	Investigation of the effect of different linker chemotypes on the inhibition of histone deacetylases (HDACs). <i>Bioorganic Chemistry</i> , 2021 , 106, 104462	5.1	4
249	Novel Pyridine-Based Hydroxamates and 2'-Aminoanilides as Histone Deacetylase Inhibitors: Biochemical Profile and Anticancer Activity. <i>ChemMedChem</i> , 2021 , 16, 989-999	3.7	2
248	Inhibitors of histone deacetylase 6 based on a novel 3-hydroxy-isoxazole zinc binding group. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2021 , 36, 2080-2086	5.6	3
247	Epigenetics in acute myeloid leukemia 2021 , 447-469		
246	The Role of Necroptosis: Biological Relevance and Its Involvement in Cancer. <i>Cancers</i> , 2021 , 13,	6.6	9
245	Regulatory Interplay between miR-181a-5p and Estrogen Receptor Signaling Cascade in Breast Cancer. <i>Cancers</i> , 2021 , 13,	6.6	5
244	Metabolite Profile and In Vitro Beneficial Effects of Black Garlic (L.) Polar Extract. <i>Nutrients</i> , 2021 , 13,	6.7	1
243	Outer Membrane Vesicles Derived from Are a Driving Force for Horizontal Gene Transfer. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	5
242	SARS-CoV-2 spike protein detection through a plasmonic D-shaped plastic optical fiber aptasensor. <i>Talanta</i> , 2021 , 233, 122532	6.2	25
241	MRI Radiomics in Prostate Cancer: A Reliability Study.. <i>Frontiers in Oncology</i> , 2021 , 11, 805137	5.3	0
240	HDAC6 Inhibition Extinguishes Autophagy in Cancer: Recent Insights.. <i>Cancers</i> , 2021 , 13,	6.6	1
239	Outer Membrane Vesicles Derived from Influence the miRNA Expression Profile in Human Bronchial Epithelial BEAS-2B Cells. <i>Microorganisms</i> , 2020 , 8,	4.9	9
238	Molecular Docking Simulations on Histone Deacetylases (HDAC)-1 and -2 to Investigate the Flavone Binding. <i>Biomedicines</i> , 2020 , 8,	4.8	11
237	The Cannabinoid Receptor CB1 Stabilizes Sperm Chromatin Condensation Status During Epididymal Transit by Promoting Disulphide Bond Formation. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	5

236	Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium. <i>Pharmacological Research</i> , 2020 , 157, 104781	10.2	31
235	A New Family of Jumonji C Domain-Containing KDM Inhibitors Inspired by Natural Product Purpurogallin. <i>Frontiers in Chemistry</i> , 2020 , 8, 312	5	8
234	The KDM Inhibitor GSKJ4 Triggers CREB Downregulation via a Protein Kinase A and Proteasome-Dependent Mechanism in Human Acute Myeloid Leukemia Cells. <i>Frontiers in Oncology</i> , 2020 , 10, 799	5.3	6
233	The Pan-Sirtuin Inhibitor MC2494 Regulates Mitochondrial Function in a Leukemia Cell Line. <i>Frontiers in Oncology</i> , 2020 , 10, 820	5.3	4
232	Novel Quinoline Compounds Active in Cancer Cells through Coupled DNA Methyltransferase Inhibition and Degradation. <i>Cancers</i> , 2020 , 12,	6.6	3
231	Blocks Proliferation in Chronic Myelogenous Leukemia via the BCR-ABL/STAT5 Pathway. <i>Cells</i> , 2020 , 9,	7.9	5
230	Comparative Phytochemical Characterization, Genetic Profile, and Antiproliferative Activity of Polyphenol-Rich Extracts from Pigmented Tubers of Different Varieties. <i>Molecules</i> , 2020 , 25,	4.8	15
229	Two novel SIRT1 activators, SCIC2 and SCIC2.1, enhance SIRT1-mediated effects in stress response and senescence. <i>Epigenetics</i> , 2020 , 15, 664-683	5.7	17
228	Feasibility of next-generation sequencing in clinical practice: results of a pilot study in the Department of Precision Medicine at the University of Campania 'Luigi Vanvitelli'. <i>ESMO Open</i> , 2020 , 5,	6	6
227	Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes. <i>EMBO Reports</i> , 2020 , 21, e51028	6.5	0
226	Marine-Derived Secondary Metabolites as Promising Epigenetic Bio-Compounds for Anticancer Therapy. <i>Marine Drugs</i> , 2020 , 19,	6	3
225	MicroRNA-Assisted Hormone Cell Signaling in Colorectal Cancer Resistance. <i>Cells</i> , 2020 , 10,	7.9	1
224	Histone demethylase inhibitors and their potential in cancer treatment 2020 , 143-177		
223	Design of Dual Inhibitors of Histone Deacetylase 6 and Heat Shock Protein 90. <i>ACS Omega</i> , 2020 , 5, 11473-11480	3.9	1480
222	DOT1L: a key target in normal chromatin remodelling and in mixed-lineage leukaemia treatment. <i>Epigenetics</i> , 2020 , 15, 439-453	5.7	24
221	Preclinical and Clinical Epigenetic-Based Reconsideration of Beckwith-Wiedemann Syndrome. <i>Frontiers in Genetics</i> , 2020 , 11, 563718	4.5	4
220	Spiroindoline-Capped Selective HDAC6 Inhibitors: Design, Synthesis, Structural Analysis, and Biological Evaluation. <i>ACS Medicinal Chemistry Letters</i> , 2020 , 11, 2268-2276	4.3	8
219	Combating Actions of Green 2D-Materials on Gram Positive and Negative Bacteria and Enveloped Viruses. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020 , 8, 569967	5.8	21

218	The Ubiquitin Proteasome System in Hematological Malignancies: New Insight into Its Functional Role and Therapeutic Options. <i>Cancers</i> , 2020 , 12,	6.6	4
217	Properly Substituted Cyclic Bis-(2-bromobenzylidene) Compounds Behaved as Dual p300/CARM1 Inhibitors and Induced Apoptosis in Cancer Cells. <i>Molecules</i> , 2020 , 25,	4.8	3
216	Extracellular Vesicle-Based Nucleic Acid Delivery: Current Cancer Therapeutic Strategies. <i>Pharmaceutics</i> , 2020 , 12,	6.4	11
215	A global network for network medicine. <i>Npj Systems Biology and Applications</i> , 2020 , 6, 29	5	6
214	SIRT1 Activation by Natural Phytochemicals: An Overview. <i>Frontiers in Pharmacology</i> , 2020 , 11, 1225	5.6	54
213	Molecular networks in Network Medicine: Development and applications. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2020 , 12, e1489	6.6	63
212	Fetal-Perinatal Exposure to Bisphenol-A Affects Quality of Spermatozoa in Adulthood Mouse. <i>International Journal of Endocrinology</i> , 2020 , 2020, 2750501	2.7	5
211	Searching for a Putative Mechanism of RIZ2 Tumor-Promoting Function in Cancer Models. <i>Frontiers in Oncology</i> , 2020 , 10, 583533	5.3	1
210	Autophagy Function and Dysfunction: Potential Drugs as Anti-Cancer Therapy. <i>Cancers</i> , 2019 , 11,	6.6	39
209	Histone Deacetylase Inhibitors Impair Vasculogenic Mimicry from Glioblastoma Cells. <i>Cancers</i> , 2019 , 11,	6.6	19
208	Identification of a novel quinoline-based DNA demethylating compound highly potent in cancer cells. <i>Clinical Epigenetics</i> , 2019 , 11, 68	7.7	18
207	BRD9 binds cell type-specific chromatin regions regulating leukemic cell survival via STAT5 inhibition. <i>Cell Death and Disease</i> , 2019 , 10, 338	9.8	15
206	Cardioprotective effect of a moderate and prolonged exercise training involves sirtuin pathway. <i>Life Sciences</i> , 2019 , 222, 140-147	6.8	16
205	Discovery of the First-in-Class GSK-3 β /HDAC Dual Inhibitor as Disease-Modifying Agent To Combat Alzheimer's Disease. <i>ACS Medicinal Chemistry Letters</i> , 2019 , 10, 469-474	4.3	20
204	Dual Tumor Suppressor and Tumor Promoter Action of Sirtuins in Determining Malignant Phenotype. <i>Frontiers in Pharmacology</i> , 2019 , 10, 38	5.6	67
203	Epigenetics: Moving Forward. <i>Methods and Principles in Medicinal Chemistry</i> , 2019 , 1-9	0.4	
202	HDAC2-dependent miRNA signature in acute myeloid leukemia. <i>FEBS Letters</i> , 2019 , 593, 2574-2584	3.8	9
201	Enzymatic and Biological Characterization of Novel Sirtuin Modulators against Cancer. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	8

200	Inhibition of Histone Demethylases LSD1 and UTX Regulates ER α Signaling in Breast Cancer. <i>Cancers</i> , 2019 , 11,	6.6	19
199	Monoacylglycerides from the Diatom Induce Selective Cell Death in Cancer Cells. <i>Marine Drugs</i> , 2019 , 17,	6	11
198	on anti-FGFR to fight cancer resistance. <i>EMBO Molecular Medicine</i> , 2019 , 11,	12	1
197	Structure-activity relationships, biological evaluation and structural studies of novel pyrrolonaphthoxazepines as antitumor agents. <i>European Journal of Medicinal Chemistry</i> , 2019 , 162, 290-320	6.8	21
196	The HDAC inhibitor SAHA regulates CBX2 stability via a SUMO-triggered ubiquitin-mediated pathway in leukemia. <i>Oncogene</i> , 2018 , 37, 2559-2572	9.2	19
195	Pro-inflammatory cytokines activate hypoxia-inducible factor 3 β via epigenetic changes in mesenchymal stromal/stem cells. <i>Scientific Reports</i> , 2018 , 8, 5842	4.9	9
194	Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. <i>Cell Death and Differentiation</i> , 2018 , 25, 486-541	12.7	2160
193	Designing Dual Transglutaminase 2/Histone Deacetylase Inhibitors Effective at Halting Neuronal Death. <i>ChemMedChem</i> , 2018 , 13, 227-230	3.7	10
192	RIP1-HAT1-SIRT Complex Identification and Targeting in Treatment and Prevention of Cancer. <i>Clinical Cancer Research</i> , 2018 , 24, 2886-2900	12.9	24
191	HDAC inhibitors as epigenetic regulators for cancer immunotherapy. <i>International Journal of Biochemistry and Cell Biology</i> , 2018 , 98, 65-74	5.6	39
190	Novel spiroindoline HDAC inhibitors: Synthesis, molecular modelling and biological studies. <i>European Journal of Medicinal Chemistry</i> , 2018 , 157, 127-138	6.8	29
189	Forskolin Sensitizes Human Acute Myeloid Leukemia Cells to H3K27me2/3 Demethylases GSKJ4 Inhibitor via Protein Kinase A. <i>Frontiers in Pharmacology</i> , 2018 , 9, 792	5.6	8
188	Synthesis and Biological Evaluation of Tripartin, a Putative KDM4 Natural Product Inhibitor, and 1-Dichloromethylinden-1-ol Analogues. <i>ChemMedChem</i> , 2018 , 13, 1949-1956	3.7	8
187	Cancer epigenetics: Moving forward. <i>PLoS Genetics</i> , 2018 , 14, e1007362	6	211
186	Combined HAT/EZH2 modulation leads to cancer-selective cell death. <i>Oncotarget</i> , 2018 , 9, 25630-25646	3.3	5
185	Sonoporation by microbubbles as gene therapy approach against liver cancer. <i>Oncotarget</i> , 2018 , 9, 32183-32195	3.3	5
184	Multi-omics profiling reveals a distinctive epigenome signature for high-risk acute promyelocytic leukemia. <i>Oncotarget</i> , 2018 , 9, 25647-25660	3.3	11
183	Biological interactions of biocompatible and water-dispersed MoS nanosheets with bacteria and human cells. <i>Scientific Reports</i> , 2018 , 8, 16386	4.9	39

182	Epigenetic modulator UVI5008 inhibits MRSA by interfering with bacterial gyrase. <i>Scientific Reports</i> , 2018 , 8, 13117	4.9	17
181	3-Chloro-'-(2-hydroxybenzylidene) benzohydrazide: An LSD1-Selective Inhibitor and Iron-Chelating Agent for Anticancer Therapy. <i>Frontiers in Pharmacology</i> , 2018 , 9, 1006	5.6	7
180	c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 2542-2555	12.9	65
179	miR-194-5p/BCLAF1 deregulation in AML tumorigenesis. <i>Leukemia</i> , 2017 , 31, 2315-2325	10.7	41
178	Development of 1,2,4-Oxadiazoles as Potent and Selective Inhibitors of the Human Deacetylase Sirtuin 2: Structure-Activity Relationship, X-ray Crystal Structure, and Anticancer Activity. <i>Journal of Medicinal Chemistry</i> , 2017 , 60, 2344-2360	8.3	61
177	Structure-Activity Relationships on Cinnamoyl Derivatives as Inhibitors of p300 Histone Acetyltransferase. <i>ChemMedChem</i> , 2017 , 12, 1359-1368	3.7	9
176	Time-resolved analysis of DNA-protein interactions in living cells by UV laser pulses. <i>Scientific Reports</i> , 2017 , 7, 11725	4.9	9
175	MicroRNA Expression Profiling Using Agilent One-Color Microarray. <i>Methods in Molecular Biology</i> , 2017 , 1509, 169-183	1.4	5
174	Identification and characterization of PKF118-310 as a KDM4A inhibitor. <i>Epigenetics</i> , 2017 , 12, 198-205	5.7	26
173	The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs. <i>Cell Reports</i> , 2016 , 17, 2087-2100	10.6	39
172	Distinct Trends of DNA Methylation Patterning in the Innate and Adaptive Immune Systems. <i>Cell Reports</i> , 2016 , 17, 2101-2111	10.6	42
171	Secretome profiling of cytokines and growth factors reveals that neuro-glial differentiation is associated with the down-regulation of Chemokine Ligand 2 (MCP-1/CCL2) in amniotic fluid derived-mesenchymal progenitor cells. <i>Proteomics</i> , 2016 , 16, 674-88	4.8	8
170	1,4-Dihydropyridines Active on the SIRT1/AMPK Pathway Ameliorate Skin Repair and Mitochondrial Function and Exhibit Inhibition of Proliferation in Cancer Cells. <i>Journal of Medicinal Chemistry</i> , 2016 , 59, 1471-91	8.3	37
169	D-ribose-glycation of insulin prevents amyloid aggregation and produces cytotoxic adducts. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016 , 1862, 93-104	6.9	27
168	"Stockpile" of Slight Transcriptomic Changes Determines the Indirect Genotoxicity of Low-Dose BPA in Thyroid Cells. <i>PLoS ONE</i> , 2016 , 11, e0151618	3.7	21
167	MicroRNA-34a regulates doxorubicin-induced cardiotoxicity in rat. <i>Oncotarget</i> , 2016 , 7, 62312-62326	3.3	51
166	Epigenetics in Acute Myeloid Leukemia 2016 , 483-498		1
165	Sirtuin functions and modulation: from chemistry to the clinic. <i>Clinical Epigenetics</i> , 2016 , 8, 61	7.7	176

164	Synthesis of 7-alkylidene-7,12-dihydroindolo[3,2-d]benzazepine-6-(5H)-ones (7-alkylidene-paullones) by N-cyclization-oxidative Heck cascade and characterization as sirtuin modulators. <i>Organic and Biomolecular Chemistry</i> , 2015 , 13, 2800-10	3.9	20
163	ARHGEF3 controls HDACi-induced differentiation via RhoA-dependent pathways in acute myeloid leukemias. <i>Epigenetics</i> , 2015 , 10, 6-18	5.7	21
162	Glycation of Wild-Type Apomyoglobin Induces Formation of Highly Cytotoxic Oligomeric Species. <i>Journal of Cellular Physiology</i> , 2015 , 230, 2807-20	7	11
161	Antiproliferative, antibacterial and antifungal activity of the lichen <i>Xanthoria parietina</i> and its secondary metabolite parietin. <i>International Journal of Molecular Sciences</i> , 2015 , 16, 7861-75	6.3	51
160	Epigenetic-based therapy: From single- to multi-target approaches. <i>International Journal of Biochemistry and Cell Biology</i> , 2015 , 69, 121-31	5.6	32
159	Targeting Histone Deacetylases in Diseases: Where Are We?. <i>Antioxidants and Redox Signaling</i> , 2015 , 23, 99-126	8.4	89
158	Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. <i>Cell Death and Differentiation</i> , 2015 , 22, 58-73	12.7	643
157	Tumour cell population growth inhibition and cell death induction of functionalized 6-aminoquinolone derivatives. <i>Cell Proliferation</i> , 2015 , 48, 705-17	7.9	6
156	HDAC2 deregulation in tumorigenesis is causally connected to repression of immune modulation and defense escape. <i>Oncotarget</i> , 2015 , 6, 886-901	3.3	24
155	Genetic mutations in epigenetic modifiers as therapeutic targets in acute myeloid leukemia. <i>Expert Opinion on Therapeutic Targets</i> , 2015 , 19, 1187-202	6.4	11
154	Anticancer activities of anthocyanin extract from genotyped <i>Solanum tuberosum</i> L. <i>Journal of Functional Foods</i> , 2015 , 19, 584-593	5.1	29
153	Evaluation of a large library of (thiazol-2-yl)hydrazones and analogues as histone acetyltransferase inhibitors: enzyme and cellular studies. <i>European Journal of Medicinal Chemistry</i> , 2014 , 80, 569-78	6.8	43
152	Cardiomyogenesis is controlled by the miR-99a/let-7c cluster and epigenetic modifications. <i>Stem Cell Research</i> , 2014 , 12, 323-37	1.6	49
151	1,3,4-Oxadiazole-containing histone deacetylase inhibitors: anticancer activities in cancer cells. <i>Journal of Medicinal Chemistry</i> , 2014 , 57, 6259-65	8.3	73
150	Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities. <i>Journal of Medicinal Chemistry</i> , 2014 , 57, 42-55	8.3	94
149	Novel antiproliferative chimeric compounds with marked histone deacetylase inhibitory activity. <i>ACS Medicinal Chemistry Letters</i> , 2014 , 5, 973-8	4.3	10
148	Relationship between genome and epigenome--challenges and requirements for future research. <i>BMC Genomics</i> , 2014 , 15, 487	4.5	21
147	Epigenetic drugs against cancer: an evolving landscape. <i>Archives of Toxicology</i> , 2014 , 88, 1651-68	5.8	37

146	Natural compounds in epigenetics: a current view. <i>Food and Chemical Toxicology</i> , 2014 , 73, 71-83	4.7	23
145	SIRT1 inhibition affects angiogenic properties of human MSCs. <i>BioMed Research International</i> , 2014 , 2014, 783459	3	13
144	The Jumonji family: past, present and future of histone demethylases in cancer. <i>Biomolecular Concepts</i> , 2014 , 5, 209-24	3.7	20
143	Context-selective death of acute myeloid leukemia cells triggered by the novel hybrid retinoid-HDAC inhibitor MC2392. <i>Cancer Research</i> , 2014 , 74, 2328-39	10.1	30
142	Quinoline-based p300 histone acetyltransferase inhibitors with pro-apoptotic activity in human leukemia U937 cells. <i>ChemMedChem</i> , 2014 , 9, 542-8	3.7	21
141	Identification of NuRSERY, a new functional HDAC complex composed by HDAC5, GATA1, EKLF and pERK present in human erythroid cells. <i>International Journal of Biochemistry and Cell Biology</i> , 2014 , 50, 112-22	5.6	19
140	Analysis of chromatin-nuclear receptor interactions by laser-chromatin immunoprecipitation. <i>Methods in Molecular Biology</i> , 2014 , 1204, 25-34	1.4	2
139	Functions, aberrations, and advances for chromatin modulation in cancer. <i>Cancer Treatment and Research</i> , 2014 , 159, 227-39	3.5	4
138	Whole-genome bisulfite sequencing of two distinct interconvertible DNA methylomes of mouse embryonic stem cells. <i>Cell Stem Cell</i> , 2013 , 13, 360-9	18	344
137	Synthetic approaches to DNMT inhibitor SGI-1027 and effects on the U937 leukemia cell line. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013 , 23, 1631-5	2.9	9
136	tert-Butylcarbamate-containing histone deacetylase inhibitors: apoptosis induction, cytodifferentiation, and antiproliferative activities in cancer cells. <i>ChemMedChem</i> , 2013 , 8, 800-11	3.7	15
135	Novel benzofuran-estrogen and coumarin derivatives: synthesis and biological activity in K562 human leukemia cells. <i>MedChemComm</i> , 2013 , 4, 1571	5	36
134	Nuclear size as estrogen-responsive chromatin quality parameter of mouse spermatozoa. <i>General and Comparative Endocrinology</i> , 2013 , 193, 201-9	3	25
133	Histone deacetylase inhibitors: a patent review (2009 - 2011). <i>Expert Opinion on Therapeutic Patents</i> , 2013 , 23, 1-17	6.8	36
132	Up-regulation of miR-146b and down-regulation of miR-200b contribute to the cytotoxic effect of histone deacetylase inhibitors on ras-transformed thyroid cells. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, E1031-40	5.6	4
131	Antioxidant, antimicrobial and anti-proliferative activities of <i>Solanum tuberosum</i> L. var. Vitelotte. <i>Food and Chemical Toxicology</i> , 2013 , 55, 304-12	4.7	46
130	MePR: a novel human mesenchymal progenitor model with characteristics of pluripotency. <i>Stem Cells and Development</i> , 2013 , 22, 2368-83	4.4	14
129	Design, synthesis and preliminary evaluation of a series of histone deacetylase inhibitors carrying a benzodiazepine ring. <i>European Journal of Medicinal Chemistry</i> , 2013 , 66, 56-68	6.8	11

128	The class I-specific HDAC inhibitor MS-275 modulates the differentiation potential of mouse embryonic stem cells. <i>Biology Open</i> , 2013 , 2, 1070-7	2.2	13
127	Altered folate receptor 2 expression in uraemic patients on haemodialysis: implications for folate resistance. <i>Nephrology Dialysis Transplantation</i> , 2013 , 28, 1214-24	4.3	11
126	Low 17beta-estradiol levels in CNR1 knock-out mice affect spermatid chromatin remodeling by interfering with chromatin reorganization. <i>Biology of Reproduction</i> , 2013 , 88, 152	3.9	38
125	Genista sessilifolia DC. extracts induce apoptosis across a range of cancer cell lines. <i>Cell Proliferation</i> , 2013 , 46, 183-92	7.9	15
124	A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance. <i>Blood</i> , 2013 , 121, 3459-68	2.2	95
123	HDAC inhibitors repress BARD1 isoform expression in acute myeloid leukemia cells via activation of miR-19a and/or b. <i>PLoS ONE</i> , 2013 , 8, e83018	3.7	36
122	HDAC modulation and cell death in the clinic. <i>Experimental Cell Research</i> , 2012 , 318, 1229-44	4.2	48
121	Chromatin accessibility, p300, and histone acetylation define PML-RAR α and AML1-ETO binding sites in acute myeloid leukemia. <i>Blood</i> , 2012 , 120, 3058-68	2.2	51
120	ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia. <i>Blood</i> , 2012 , 120, 4038-48	2.2	82
119	New synthetic approach to paullones and characterization of their SIRT1 inhibitory activity. <i>Organic and Biomolecular Chemistry</i> , 2012 , 10, 2101-12	3.9	36
118	Trials with 'epigenetic' drugs: an update. <i>Molecular Oncology</i> , 2012 , 6, 657-82	7.9	184
117	A DNA methyltransferase modulator inspired by peyssonenyne natural product structures. <i>ChemMedChem</i> , 2012 , 7, 2101-12	3.7	3
116	UHRF1 coordinates peroxisome proliferator activated receptor gamma (PPARG) epigenetic silencing and mediates colorectal cancer progression. <i>Oncogene</i> , 2012 , 31, 5061-72	9.2	69
115	Developing novel non-hydroxamate histone deacetylase inhibitors: the chelidamic warhead. <i>MedChemComm</i> , 2012 , 3, 298-304	5	6
114	Indole-derived psammaphin A analogues as epigenetic modulators with multiple inhibitory activities. <i>Journal of Medicinal Chemistry</i> , 2012 , 55, 9467-91	8.3	43
113	Benzodeazaflavins as sirtuin inhibitors with antiproliferative properties in cancer stem cells. <i>Journal of Medicinal Chemistry</i> , 2012 , 55, 8193-7	8.3	27
112	Carprofen analogues as sirtuin inhibitors: enzyme and cellular studies. <i>ChemMedChem</i> , 2012 , 7, 1905-8	3.7	10
111	The new low-toxic histone deacetylase inhibitor S-(2) induces apoptosis in various acute myeloid leukaemia cells. <i>Journal of Cellular and Molecular Medicine</i> , 2012 , 16, 1758-65	5.6	11

110	Discovery of salermide-related sirtuin inhibitors: binding mode studies and antiproliferative effects in cancer cells including cancer stem cells. <i>Journal of Medicinal Chemistry</i> , 2012 , 55, 10937-47	8.3	70
109	Identification of PR-SET7 and EZH2 selective inhibitors inducing cell death in human leukemia U937 cells. <i>Biochimie</i> , 2012 , 94, 2308-13	4.6	24
108	Anti-leukemia activity of chaetocin via death receptor-dependent apoptosis and dual modulation of the histone methyl-transferase SUV39H1. <i>Leukemia</i> , 2012 , 26, 662-74	10.7	65
107	Sirtuins and disease: the road ahead. <i>Frontiers in Pharmacology</i> , 2012 , 3, 4	5.6	120
106	miRNA-mediated deregulation in leukemia. <i>Frontiers in Genetics</i> , 2012 , 3, 252	4.5	9
105	Nonlinear protein - nucleic acid crosslinking induced by femtosecond UV laser pulses in living cells. <i>Laser Physics Letters</i> , 2012 , 9, 234-239	1.5	21
104	Design, synthesis, and biological evaluation of 2-aminobenzanilide derivatives as potent and selective HDAC inhibitors. <i>ChemMedChem</i> , 2012 , 7, 1256-66	3.7	14
103	BLUEPRINT to decode the epigenetic signature written in blood. <i>Nature Biotechnology</i> , 2012 , 30, 224-6	44.5	261
102	<i>Psidium guajava</i> L. anti-neoplastic effects: induction of apoptosis and cell differentiation. <i>Cell Proliferation</i> , 2012 , 45, 22-31	7.9	33
101	Molecular pathways: the complexity of the epigenome in cancer and recent clinical advances. <i>Clinical Cancer Research</i> , 2012 , 18, 5526-34	12.9	23
100	Epigenetic multiple modulators. <i>Current Topics in Medicinal Chemistry</i> , 2011 , 11, 2749-87	3	8
99	Histone deacetylase inhibitors: recent insights from basic to clinical knowledge & patenting of anti-cancer actions. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2011 , 6, 131-45	2.6	25
98	Novel cinnamyl hydroxyamides and 2-aminoanilides as histone deacetylase inhibitors: apoptotic induction and cytodifferentiation activity. <i>ChemMedChem</i> , 2011 , 6, 698-712	3.7	13
97	Carbamate prodrug concept for hydroxamate HDAC inhibitors. <i>ChemMedChem</i> , 2011 , 6, 1193-8	3.7	29
96	Total synthesis of the proposed structures of the DNA methyl transferase inhibitors peyssonenyne, and structural revision of peyssonenyne B. <i>Organic and Biomolecular Chemistry</i> , 2011 , 9, 6979-87	3.9	13
95	Epigenetic profiling of the antitumor natural product psammaphin A and its analogues. <i>Bioorganic and Medicinal Chemistry</i> , 2011 , 19, 3637-49	3.4	45
94	Modulation of the activity of histone acetyltransferases by long chain alkylidenemalonates (LoCAMs). <i>Bioorganic and Medicinal Chemistry</i> , 2011 , 19, 3690-701	3.4	27
93	Simplification of the tetracyclic SIRT1-selective inhibitor MC2141: coumarin- and pyrimidine-based SIRT1/2 inhibitors with different selectivity profile. <i>Bioorganic and Medicinal Chemistry</i> , 2011 , 19, 3659-68	3.4	28

92	Death receptor pathway activation and increase of ROS production by the triple epigenetic inhibitor UVI5008. <i>Molecular Cancer Therapeutics</i> , 2011 , 10, 2394-404	6.1	46
91	Nεlysine acetylation determines dissociation from GAP junctions and lateralization of connexin 43 in normal and dystrophic heart. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 2795-800	11.5	82
90	Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation. <i>Oncogene</i> , 2010 , 29, 105-16	9.2	60
89	Epigenetic silencing of peroxisome proliferator-activated receptor α is a biomarker for colorectal cancer progression and adverse patients' outcome. <i>PLoS ONE</i> , 2010 , 5, e14229	3.7	65
88	A gradient of 2-arachidonoylglycerol regulates mouse epididymal sperm cell start-up. <i>Biology of Reproduction</i> , 2010 , 82, 451-8	3.9	67
87	HDACs class II-selective inhibition alters nuclear receptor-dependent differentiation. <i>Journal of Molecular Endocrinology</i> , 2010 , 45, 219-28	4.5	48
86	Cannabinoid receptor 1 influences chromatin remodeling in mouse spermatids by affecting content of transition protein 2 mRNA and histone displacement. <i>Endocrinology</i> , 2010 , 151, 5017-29	4.8	64
85	Targeting epigenetic networks with polypharmacology: a new avenue to tackle cancer. <i>Epigenomics</i> , 2010 , 2, 731-42	4.4	32
84	Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7-modified analogues. <i>Journal of Medicinal Chemistry</i> , 2010 , 53, 4654-67	8.3	71
83	Characterization of sirtuin inhibitors in nematodes expressing a muscular dystrophy protein reveals muscle cell and behavioral protection by specific sirtinol analogues. <i>Journal of Medicinal Chemistry</i> , 2010 , 53, 1407-11	8.3	40
82	Histone deacetylase inhibitors: clinical implications for hematological malignancies. <i>Clinical Epigenetics</i> , 2010 , 1, 25-44	7.7	13
81	PML-RARalpha/RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia. <i>Cancer Cell</i> , 2010 , 17, 173-85	24.3	239
80	Identification of tri- and tetracyclic pyrimidinediones as sirtuin inhibitors. <i>ChemMedChem</i> , 2010 , 5, 674-73,7	3.7	38
79	New anacardic acid-inspired benzamides: histone lysine acetyltransferase activators. <i>ChemMedChem</i> , 2010 , 5, 1530-40	3.7	16
78	Impact of histone deacetylase inhibitors SAHA and MS-275 on DNA repair pathways in human mesenchymal stem cells. <i>Journal of Cellular Physiology</i> , 2010 , 225, 537-44	7	25
77	Evaluation of histone deacetylases as drug targets in Huntington's disease models. Study of HDACs in brain tissues from R6/2 and CAG140 knock-in HD mouse models and human patients and in a neuronal HD cell model. <i>PLOS Currents</i> , 2010 , 2,		28
76	Histone deacetylase inhibitors promote apoptosis and senescence in human mesenchymal stem cells. <i>Stem Cells and Development</i> , 2009 , 18, 573-81	4.4	55
75	Growth factor-antagonized rexinoid apoptosis involves permissive PPARGgamma/RXR heterodimers to activate the intrinsic death pathway by NO. <i>Cancer Cell</i> , 2009 , 16, 220-31	24.3	29

74	Pyrrole-based hydroxamates and 2-aminoanilides: histone deacetylase inhibition and cellular activities. <i>ChemMedChem</i> , 2009 , 4, 1411-5	3.7	7
73	Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes. <i>EMBO Reports</i> , 2009 , 10, 776-82	6.5	109
72	Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect. <i>Oncogene</i> , 2009 , 28, 781-91	9.1	221
71	Identification of 4-hydroxyquinolines inhibitors of p300/CBP histone acetyltransferases. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009 , 19, 1132-5	2.9	55
70	Novel N-hydroxybenzamide-based HDAC inhibitors with branched CAP group. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009 , 19, 6284-8	2.9	11
69	Epigenetic therapies in haematological malignancies: searching for true targets. <i>European Journal of Cancer</i> , 2009 , 45, 1137-1145	7.5	40
68	Effect of bisphenol A with or without enzyme treatment on the proliferation and viability of MCF-7 cells. <i>Environment International</i> , 2009 , 35, 21-6	12.9	34
67	TNF-related apoptosis-inducing ligand: signalling of a 'smart' molecule. <i>International Journal of Biochemistry and Cell Biology</i> , 2009 , 41, 460-6	5.6	22
66	Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead. <i>International Journal of Biochemistry and Cell Biology</i> , 2009 , 41, 199-213	5.6	158
65	New pyrrole-based histone deacetylase inhibitors: binding mode, enzyme- and cell-based investigations. <i>International Journal of Biochemistry and Cell Biology</i> , 2009 , 41, 235-47	5.6	20
64	Study of 1,4-dihydropyridine structural scaffold: discovery of novel sirtuin activators and inhibitors. <i>Journal of Medicinal Chemistry</i> , 2009 , 52, 5496-504	8.3	117
63	Molecular analysis of the apoptotic effects of BPA in acute myeloid leukemia cells. <i>Journal of Translational Medicine</i> , 2009 , 7, 48	8.5	23
62	"Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence. <i>Retrovirology</i> , 2009 , 6, 52	3.6	90
61	Histone acetyltransferase inhibitors and preclinical studies. <i>Expert Opinion on Therapeutic Patents</i> , 2009 , 19, 761-74	6.8	76
60	HDAC-class II specific inhibition involves HDAC proteasome-dependent degradation mediated by RANBP2. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2008 , 1783, 2030-8	4.9	44
59	Molecular analysis of the effects of Piroxicam and Cisplatin on mesothelioma cells growth and viability. <i>Journal of Translational Medicine</i> , 2008 , 6, 27	8.5	15
58	epigenetic multiple ligands: mixed histone/protein methyltransferase, acetyltransferase, and class III deacetylase (sirtuin) inhibitors. <i>Journal of Medicinal Chemistry</i> , 2008 , 51, 2279-90	8.3	125
57	HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 19183-7	11.5	212

56	Competitive or noncompetitive, that's the question: research toward histone deacetylase inhibitors. <i>Molecular Cancer Therapeutics</i> , 2008 , 7, 1007-12	6.1	24
55	Specific activity of class II histone deacetylases in human breast cancer cells. <i>Molecular Cancer Research</i> , 2008 , 6, 1908-19	6.6	82
54	Regulation of interleukin-8 gene at a distinct site of its promoter by CCAAT enhancer-binding protein homologous protein in prostaglandin E2-treated human T cells. <i>Journal of Biological Chemistry</i> , 2008 , 283, 29760-9	5.4	13
53	Synthesis of benzamides related to anacardic acid and their histone acetyltransferase (HAT) inhibitory activities. <i>ChemMedChem</i> , 2008 , 3, 1435-42	3.7	47
52	Laccase treatment impairs bisphenol A-induced cancer cell proliferation affecting estrogen receptor alpha-dependent rapid signals. <i>IUBMB Life</i> , 2008 , 60, 843-52	4.7	59
51	The <i>Helicobacter pylori</i> 's protein VacA has direct effects on the regulation of cell cycle and apoptosis in gastric epithelial cells. <i>Journal of Cellular Physiology</i> , 2008 , 214, 582-7	7	34
50	Design, synthesis and biological evaluation of novel compounds with conjugated structure as anti-tumor agents. <i>Bioorganic and Medicinal Chemistry</i> , 2008 , 16, 7992-8002	3.4	10
49	Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: histone deacetylase inhibition and in-cell activities. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008 , 18, 2530-5	2.9	18
48	Identification of long chain alkylidenemalonates as novel small molecule modulators of histone acetyltransferases. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008 , 18, 2788-92	2.9	91
47	Synthesis and biological validation of novel synthetic histone/protein methyltransferase inhibitors. <i>ChemMedChem</i> , 2007 , 2, 987-91	3.7	48
46	RAR and RXR modulation in cancer and metabolic disease. <i>Nature Reviews Drug Discovery</i> , 2007 , 6, 793-804	6.1	393
45	Design of selective nuclear receptor modulators: RAR and RXR as a case study. <i>Nature Reviews Drug Discovery</i> , 2007 , 6, 811-20	6.1	210
44	Endocannabinoid control of sperm motility: the role of epididymus. <i>General and Comparative Endocrinology</i> , 2007 , 153, 320-2	3	62
43	Identification of two new synthetic histone deacetylase inhibitors that modulate globin gene expression in erythroid cells from healthy donors and patients with thalassemia. <i>Molecular Pharmacology</i> , 2007 , 72, 1111-23	4.3	27
42	Novel pyrrole-containing histone deacetylase inhibitors endowed with cytodifferentiation activity. <i>International Journal of Biochemistry and Cell Biology</i> , 2007 , 39, 1510-22	5.6	11
41	Feijoa sellowiana derived natural Flavone exerts anti-cancer action displaying HDAC inhibitory activities. <i>International Journal of Biochemistry and Cell Biology</i> , 2007 , 39, 1902-14	5.6	78
40	Bispyridinium dienes: histone deacetylase inhibitors with selective activities. <i>Journal of Medicinal Chemistry</i> , 2007 , 50, 2497-505	8.3	46
39	Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells. <i>Journal of Cellular Biochemistry</i> , 2006 , 98, 1163-84	4.7	37

38	Piroxicam and cisplatin in a mouse model of peritoneal mesothelioma. <i>Clinical Cancer Research</i> , 2006 , 12, 6133-43	12.9	37
37	Small-molecule inhibitors of histone acetyltransferase activity: identification and biological properties. <i>Journal of Medicinal Chemistry</i> , 2006 , 49, 6897-907	8.3	119
36	Synthesis and biological properties of novel, uracil-containing histone deacetylase inhibitors. <i>Journal of Medicinal Chemistry</i> , 2006 , 49, 6046-56	8.3	51
35	TRAIL: at the center of drugable anti-tumor pathways. <i>Cell Cycle</i> , 2005 , 4, 914-8	4.7	13
34	Acute myeloid leukemia: therapeutic impact of epigenetic drugs. <i>International Journal of Biochemistry and Cell Biology</i> , 2005 , 37, 1752-62	5.6	40
33	Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides. <i>Journal of Medicinal Chemistry</i> , 2005 , 48, 3344-53	8.3	179
32	Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. <i>Nature Medicine</i> , 2005 , 11, 71-6	50.5	472
31	Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. <i>Nature Medicine</i> , 2005 , 11, 77-84	50.5	516
30	Molecular pathways involved in neural in vitro differentiation of marrow stromal stem cells. <i>Journal of Cellular Biochemistry</i> , 2005 , 94, 645-55	4.7	97
29	Rexinoid-triggered differentiation and tumor-selective apoptosis of acute myeloid leukemia by protein kinase A-mediated desubordination of retinoid X receptor. <i>Cancer Research</i> , 2005 , 65, 8754-65	10.1	100
28	Retinoids and TRAIL: two cooperating actors to fight against cancer. <i>Vitamins and Hormones</i> , 2004 , 67, 319-45	2.5	15
27	Estrogens and progesterone promote persistent CCND1 gene activation during G1 by inducing transcriptional derepression via c-Jun/c-Fos/estrogen receptor (progesterone receptor) complex assembly to a distal regulatory element and recruitment of cyclin D1 to its own gene promoter. <i>Molecular and Cellular Biology</i> , 2004 , 24, 7249-54	4.8	132
26	A genomic view of estrogen actions in human breast cancer cells by expression profiling of the hormone-responsive transcriptome. <i>Journal of Molecular Endocrinology</i> , 2004 , 32, 719-75	4.5	74
25	Retinoids: potential in cancer prevention and therapy. <i>Expert Reviews in Molecular Medicine</i> , 2004 , 6, 1-23	6.7	82
24	Molecular identification of ERalpha-positive breast cancer cells by the expression profile of an intrinsic set of estrogen regulated genes. <i>Journal of Cellular Physiology</i> , 2004 , 200, 440-50	7	39
23	Retinoic-acid-induced apoptosis in leukemia cells. <i>Trends in Molecular Medicine</i> , 2004 , 10, 508-15	11.5	36
22	Leukemia: beneficial actions of retinoids and rexinoids. <i>International Journal of Biochemistry and Cell Biology</i> , 2004 , 36, 178-82	5.6	18
21	Distinct signaling pathways mediate stimulation of cell cycle progression and prevention of apoptotic cell death by estrogen in rat pituitary tumor PR1 cells. <i>Molecular Biology of the Cell</i> , 2003 , 14, 5051-9	3.5	15

20	Nuclear receptor superfamily: Principles of signaling. <i>Pure and Applied Chemistry</i> , 2003 , 75, 1619-1664	2.1	37
19	Regulation of nuclear receptor and cofactor expression in breast cancer cell lines. <i>European Journal of Endocrinology</i> , 2003 , 148, 469-79	6.5	15
18	Coexpression of Helicobacter pylori's proteins CagA and HspB induces cell proliferation in AGS gastric epithelial cells, independently from the bacterial infection. <i>Cancer Research</i> , 2003 , 63, 6350-6	10.1	27
17	Decryption of the retinoid death code in leukemia. <i>Journal of Clinical Immunology</i> , 2002 , 22, 117-23	5.7	7
16	Inhibition of human breast cancer cell growth by blockade of the mevalonate-protein prenylation pathway is not prevented by overexpression of cyclin D1. <i>Breast Cancer Research and Treatment</i> , 2001 , 67, 23-33	4.4	2
15	Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. <i>Nature Medicine</i> , 2001 , 7, 680-6	50.5	305
14	The promise of retinoids to fight against cancer. <i>Nature Reviews Cancer</i> , 2001 , 1, 181-93	31.3	649
13	Autonomous retinoid death signaling is suppressed by converging signaling pathways in immature leukemia cells. <i>Molecular Endocrinology</i> , 2001 , 15, 1154-69		44
12	Cell type-specific induction of cyclin D and cyclin-dependent kinase inhibitor p27(kip1) expression by estrogen in rat endometrium. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2001 , 78, 193-9	5.1	12
11	Nuclear receptors in cell life and death. <i>Trends in Endocrinology and Metabolism</i> , 2001 , 12, 460-8	8.8	98
10	Estrogens do not modify MAP kinase-dependent nuclear signaling during stimulation of early G(1) progression in human breast cancer cells. <i>Cancer Research</i> , 2001 , 61, 6360-6	10.1	24
9	The antiestrogen ICI 182,780 inhibits proliferation of human breast cancer cells by interfering with multiple, sequential estrogen-regulated processes required for cell cycle completion. <i>Molecular and Cellular Endocrinology</i> , 2000 , 165, 199-209	4.4	21
8	RAR-independent RXR signaling induces t(15;17) leukemia cell maturation. <i>EMBO Journal</i> , 1999 , 18, 7011-8	1.3	97
7	Constitutive overexpression of cyclin D1 does not prevent inhibition of hormone-responsive human breast cancer cell growth by antiestrogens. <i>Cancer Research</i> , 1998 , 58, 871-6	10.1	22
6	Estrogen induces early and timed activation of cyclin-dependent kinases 4, 5, and 6 and increases cyclin messenger ribonucleic acid expression in rat uterus. <i>Endocrinology</i> , 1997 , 138, 978-84	4.8	73
5	Stimulation of human breast cancer MCF-7 cells with estrogen prevents cell cycle arrest by HMG-CoA reductase inhibitors. <i>Biochemical and Biophysical Research Communications</i> , 1996 , 220, 864-70	3.4	34
4	17 beta-Estradiol overcomes a G1 block induced by HMG-CoA reductase inhibitors and fosters cell cycle progression without inducing ERK-1 and -2 MAP kinases activation. <i>Oncogene</i> , 1996 , 12, 753-63	9.2	46
3	17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. <i>Oncogene</i> , 1996 , 12, 2315-24	9.2	219

2	Estrogen Induces Early and Timed Activation of Cyclin-Dependent Kinases 4, 5, and 6 and Increases Cyclin Messenger Ribonucleic Acid Expression in Rat Uterus	18
1	Dual HDACBRD4 inhibitors endowed with antitumor and antihyperalgesic activity. <i>Medicinal Chemistry Research</i> ,1	2.2